 | |
| Clinical data | |
|---|---|
| Other names | EPI-7386 |
| Routes of administration | By mouth |
| Drug class | N-Terminal domain antiandrogen |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C24H24Cl2N4O4S |
| Molar mass | 535.44 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Masofaniten, also known by its developmental code nameEPI-7386, is anN-terminal domain antiandrogen, orantagonist of theN-terminal domain (NTD) of theandrogen receptor (AR), which is under development for the treatment ofprostate cancer.[1][2][3][4] The compound was developed as a successor of previous drugs in the EPI series such asEPI-001,ralaniten (EPI-002), andralaniten acetate (EPI-506).[2][3][4] Masofaniten shows 20-fold higherantiandrogenicpotency than ralanitenin vitro (IC50Tooltip Half-maximal inhibitory concentration = 535 nM vs. 9,580 nM, respectively), as well as greater stability in humanhepatocytes.[2][3][4] It was planned to enterphase Iclinical trials in 2020.[4] Preliminary results of a phase I/II clinical trial were published in 2023.[5][6] The development of masofaniten was discontinued in 2024 following disappointing clinical trial results.[1][7]
 | Thisdrug article relating to thegenito-urinary system is astub. You can help Wikipedia byadding missing information. |